Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years

Sebastian Giebel, Myriam Labopin, Jerzy Holowiecki, Boris Labar, Mieczyslaw Komarnicki, Vladimir Koza, T. Masszi, Martin Mistrik, Andrzej Lange, Andrzej Hellmann, Antonin Vitek, Joze Pretnar, Jiri Mayer, Piotr Rzepecki, Karel Indrak, Wieslaw Wiktor-Jedrzejczak, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Slawomira Kyrcz-Krzemien, Vanderson Rocha

Research output: Article

25 Citations (Scopus)

Abstract

The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58±2%, 19±2%, and 23±2%, respectively. The cumulative incidence of NRM decreased from 22±2% for patients treated between 1990 and 2002 to 15±3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.

Original languageEnglish
Pages (from-to)1005-1013
Number of pages9
JournalAnnals of Hematology
Volume88
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Leukemia
Mortality
Incidence
Recurrence
Eastern Europe
Survival
Stem Cell Transplantation
Multivariate Analysis
Survival Rate
Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. / Giebel, Sebastian; Labopin, Myriam; Holowiecki, Jerzy; Labar, Boris; Komarnicki, Mieczyslaw; Koza, Vladimir; Masszi, T.; Mistrik, Martin; Lange, Andrzej; Hellmann, Andrzej; Vitek, Antonin; Pretnar, Joze; Mayer, Jiri; Rzepecki, Piotr; Indrak, Karel; Wiktor-Jedrzejczak, Wieslaw; Wojnar, Jerzy; Krawczyk-Kulis, Malgorzata; Kyrcz-Krzemien, Slawomira; Rocha, Vanderson.

In: Annals of Hematology, Vol. 88, No. 10, 2009, p. 1005-1013.

Research output: Article

Giebel, S, Labopin, M, Holowiecki, J, Labar, B, Komarnicki, M, Koza, V, Masszi, T, Mistrik, M, Lange, A, Hellmann, A, Vitek, A, Pretnar, J, Mayer, J, Rzepecki, P, Indrak, K, Wiktor-Jedrzejczak, W, Wojnar, J, Krawczyk-Kulis, M, Kyrcz-Krzemien, S & Rocha, V 2009, 'Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years', Annals of Hematology, vol. 88, no. 10, pp. 1005-1013. https://doi.org/10.1007/s00277-009-0719-5
Giebel, Sebastian ; Labopin, Myriam ; Holowiecki, Jerzy ; Labar, Boris ; Komarnicki, Mieczyslaw ; Koza, Vladimir ; Masszi, T. ; Mistrik, Martin ; Lange, Andrzej ; Hellmann, Andrzej ; Vitek, Antonin ; Pretnar, Joze ; Mayer, Jiri ; Rzepecki, Piotr ; Indrak, Karel ; Wiktor-Jedrzejczak, Wieslaw ; Wojnar, Jerzy ; Krawczyk-Kulis, Malgorzata ; Kyrcz-Krzemien, Slawomira ; Rocha, Vanderson. / Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. In: Annals of Hematology. 2009 ; Vol. 88, No. 10. pp. 1005-1013.
@article{7f2c48b8b2e940a99553a2631c49a217,
title = "Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years",
abstract = "The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58±2{\%}, 19±2{\%}, and 23±2{\%}, respectively. The cumulative incidence of NRM decreased from 22±2{\%} for patients treated between 1990 and 2002 to 15±3{\%} for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.",
keywords = "Acute leukemia, Leukemia-free survival, Matched related donor HSCT, Nonrelapse mortality, Prognostic factors",
author = "Sebastian Giebel and Myriam Labopin and Jerzy Holowiecki and Boris Labar and Mieczyslaw Komarnicki and Vladimir Koza and T. Masszi and Martin Mistrik and Andrzej Lange and Andrzej Hellmann and Antonin Vitek and Joze Pretnar and Jiri Mayer and Piotr Rzepecki and Karel Indrak and Wieslaw Wiktor-Jedrzejczak and Jerzy Wojnar and Malgorzata Krawczyk-Kulis and Slawomira Kyrcz-Krzemien and Vanderson Rocha",
year = "2009",
doi = "10.1007/s00277-009-0719-5",
language = "English",
volume = "88",
pages = "1005--1013",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years

AU - Giebel, Sebastian

AU - Labopin, Myriam

AU - Holowiecki, Jerzy

AU - Labar, Boris

AU - Komarnicki, Mieczyslaw

AU - Koza, Vladimir

AU - Masszi, T.

AU - Mistrik, Martin

AU - Lange, Andrzej

AU - Hellmann, Andrzej

AU - Vitek, Antonin

AU - Pretnar, Joze

AU - Mayer, Jiri

AU - Rzepecki, Piotr

AU - Indrak, Karel

AU - Wiktor-Jedrzejczak, Wieslaw

AU - Wojnar, Jerzy

AU - Krawczyk-Kulis, Malgorzata

AU - Kyrcz-Krzemien, Slawomira

AU - Rocha, Vanderson

PY - 2009

Y1 - 2009

N2 - The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58±2%, 19±2%, and 23±2%, respectively. The cumulative incidence of NRM decreased from 22±2% for patients treated between 1990 and 2002 to 15±3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.

AB - The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58±2%, 19±2%, and 23±2%, respectively. The cumulative incidence of NRM decreased from 22±2% for patients treated between 1990 and 2002 to 15±3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.

KW - Acute leukemia

KW - Leukemia-free survival

KW - Matched related donor HSCT

KW - Nonrelapse mortality

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=69249235616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249235616&partnerID=8YFLogxK

U2 - 10.1007/s00277-009-0719-5

DO - 10.1007/s00277-009-0719-5

M3 - Article

C2 - 19301005

AN - SCOPUS:69249235616

VL - 88

SP - 1005

EP - 1013

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -